Safety readout on ViewRay's SMART study may hit before year-end, says Baird
Baird analyst Jason Bednar says his recent review of ViewRay's prospective pancreatic trial, SMART, on clinicaltrials.gov revealed trial details have been updated within the last week to reflect three additional sites are now recruiting patients. The primary completion date of the study was pulled forward to May 2021 versus the previously listed November 2023, he notes, arguing that the pull-forward could be a positive indicator there have not been any early safety issues with the first cohort of patients in the study. If true, Bednar suspects the safety readout on the SMART study may be on track to hit before the end of 2019. The analyst has an Outperform rating and $13 price target on the shares.